Date of event
Thursday, April 30, 2020 - 5:00 pm -
Thursday, April 30, 2020 - 6:00 pm
Continuing Education Credits

Content Contributor

AASLD COVID-19 Working Group


  • Kimberly Ann Brown, MD, FAST, FAASLD, AGAF
    Henry Ford Health System
  • Emmanuel Thomas, MD, PhD, FAASLD
    University of Miami School of Medicine
  • Laura M. Kulik, MD
    Northwestern University Feinberg School of Medicine

Moderator / Presenter

  • Brendan M. McGuire, MD
    University of Alabama at Birmingham


  • Jaime Chu, MD
    Icahn School of Medicine at Mount Sinai
  • Oren K. Fix, MD, MSc, FAASLD
    Swedish Medical Center
  • Patricia Harren, DNP
    Columbia University Medical Center
  • David C. Mulligan, MD, FAASLD
    Yale University
  • Daniel S. Pratt, MD, FAASLD
    Massachusetts General Hospital
  • Elizabeth C. Verna, MD, MS
    Columbia University Medical Center


  • Jorge A. Bezerra, MD, FAASLD
    Cincinnati Children's Hospital Medical Center
  • Raymond T. Chung, MD, FAASLD
    Massachusetts General Hospital
  • Robert J. Fontana, MD, FAASLD
    University of Michigan Hospitals and Health
  • Bilal Hameed, MD
    University of California, San Francisco
  • K. Rajender Reddy, MD, FAASLD
    University of Pennsylvania Medical Center
  • Mark W. Russo, MD, MPH, FAASLD
    Carolinas Medical Center


As the COVID-19 pandemic continues to evolve, AASLD is committed to helping our members and the broader community respond to increasing challenges and complexities.

This is the fourth in a series of webinars AASLD is dedicating to ongoing discoveries and discussions about COVID-19 and how it impacts the care of liver patients. This webinar will:

  • Describe updates to the COVID-19 pandemic's effect on the liver and its impact on hepatology and liver transplant providers.
  • Help attendees to understand and review management strategies in patients with COVID-19 and chronic liver disease.
  • Provide information regarding diagnostic antibody tests for SARS-CoV2 exposure and review data on the possibility of subsequent immune protection from COVID-19.

Watch the Webinar / Download the Presentation


Download the slide presentation.

Presenter Bios

Kimberly A. Brown, MD, FAST, FAASLD, AGAF

Dr. Kimberly A. Brown is the Chief of Gastroenterology and Hepatology at Henry Ford Hospital in Detroit. She joined the Henry Ford Medical Group in 1995 as medical director of the liver transplant program and was appointed Chief of the division of gastroenterology and hepatology in 2003. In addition, she served as the program director for the GI fellowship program from 2003 to 2008.

Dr. Brown received her undergraduate degree from the University of Michigan in 1981. She completed her medical degree at Wayne State University in 1985. Dr. Brown completed both her residency in internal medicine as well as her fellowship in gastroenterology at the University of Michigan in 1992 and was named chief medical resident in 1984-85.

Dr. Brown is a member of the American Gastroenterology Association, the American Association for the Study of Liver Disease, the American College of Gastroenterology, The European Association for the Study of Liver Disease, and the American Society of Transplantation. She served on the Board of Governors of the Henry Ford Medical Group for nine years, the Henry Ford Hospital and System Network Board for three years, and was past co-chair of the Michigan Chapter of the American Liver Foundation. She has served as the treasurer of the Board of the American Society of Transplantation and is involved with several committees for both the society and hospital. She is a past member of the UNOS Liver and Intestines Committee and the Executive Board for the Liver and Intestines Community of Practice for the AST. Dr. Brown is currently serving as secretary to AASLD.

As Chief of Gastroenterology and Hepatology and past medical director of liver transplantation, Dr. Brown sees and manages patients with complex liver disease both before and after liver transplantation. In conjunction with Dr Abouljoud, she worked to develop the leading liver transplant program in the State of Michigan. As fellowship director, she managed a fellowship program of 12 GI/liver fellows and continues to be involved in structuring and monitoring their education and academic success. She has published more than 70 articles, 80 abstracts and eight book chapters/reviews and is a very active clinical investigator in viral hepatitis, advanced liver disease and post liver transplant management. She is also a past award winner of the Castle Connelly National Top Doc Award for Clinical Excellence and Henry Ford Medical Group Fred Whitehouse Award for Clinical Excellence. She is also the Associate Director of the HFH Transplant Institute.

Photo of Dr. Kimberly A. Brown


Emmanuel Thomas, MD, PhD, FAASLD

Dr. Emmanuel Thomas is an associate professor at the University of Miami Miller School of Medicine in the Department of Microbiology. He has trained with Doctors Jake Liang at the NIH, and Michael Fried at UNC-Chapel Hill. He is co-director of the CLIA certified diagnostic hepatology laboratory in the Schiff Center for Liver Diseases. Dr. Thomas has an independent integrated, multidisciplinary clinical research laboratory focused on viral hepatitis and hepatocellular carcinoma. The program is funded by the NIH through a five-year, renewable Outstanding Investigator R35 Award focused on host defense and viral infections. He also has funding from the Florida Department of Health and Gilead Sciences. Dr. Thomas serves on the National Board of Directors for the American Liver Foundation.

photo of Dr. Emmanuel Thomas


Laura M. Kulik, MD

I am a Professor of Medicine in the Division of Gastroenterology and Hepatology, and am Certified in both Gastroenterology and Hepatology and in Transplant Hepatology. My major clinical research focus is on the therapy and diagnosis of hepatocellular carcinoma. I work in a multi-disciplinary medical/radiologic/surgical Liver Tumor clinic, and am involved in the recruitment of patients with HCC into clinical or pathologic trials. My major interest is on loco-regional therapy for HCC, both as a primary therapy and as a bridge to liver transplantation, including 90Yttrium radiotherapy and TACE. I am also author of the AASLD Guidelines.

Photo of Dr. Laura M. Kulik

Moderator Bio

Brendan M. McGuire, MD, MS

Dr. Brendan M. McGuire is Professor of Medicine and Medical Director of the Liver Transplant Program at the University of Alabama at Birmingham (UAB) and the Children’s of Alabama. He is also director of the UAB Transplant Hepatology Fellowship Program. Dr. McGuire has volunteered his time on various committees for the United Network for Organ Sharing (UNOS), American Society of Transplantation (AST), and American Association for the Study of Liver Disease (AASLD). He has been a member of his favorite organization AASLD since 1996. He has more than 90 peer-reviewed publications and book chapters. He has been a member of the NIH funded Acute Liver Failure Study Group and Porphyria Consortium. Most recently, he was appointed to serve on the ABIM Test and Policy Committee for Transplant Hepatology. He has won numerous teaching awards honoring his work with medical students, residents, and fellows.

Photo of Dr. Brendan M. McGuire